Drug Trial Radar · NCT03936465
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Last checked: Nov 19, 2026Latest source record: Oct 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Sep 27, 2019
Primary completion
Mar 16, 2024
Study completion Oct 1, 2024
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Stand Up To Cancer
- First posted
- May 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Arm 1 of this research study is studying an investigational drug called BMS-986158 as a possible treatment for pediatric solid tumors or lymphoma. Arm 2 of this research study is studying an investigational drug called BMS-986378 (also known as CC-90010) as a possible treatment for pediatric brain tumors or pediatric tumors that have spread to the brain.
Conditions
- Solid Tumor, Childhood
- Lymphoma
- Brain Tumor, Pediatric
Interventions
BMS-986158Drug
BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
BMS-986378Drug
BMS-986378 (also known as CC-90010) belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity RateTime frame: 28 days (first cycle)
- The Rate of Toxicities from Protocol TherapyTime frame: 2 years
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Dana Farber Cancer Institute
Boston, Massachusetts
C.S. Mott Children's Hospital
Ann Arbor, Michigan
Duke University Medical Center
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Seattle Children's Hospital
Seattle, Washington
Hospital for Sick Children
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.